Kenvue Inc. KVUE

Kenvue’s strongest current evidence is the official first-quarter filing rail: the 10-Q for the period ending 2026-03-29 reported $3.91B of revenue from contracts with customers, $767.0M of operating income, $474.0M of net income attributable to parent, and diluted EPS of $0.25 on 1.92B diluted weighted average shares. That gives KVUE a real operating story before any chart narrative is allowed into the room.

The issuer’s own site presents Kenvue as “A new view of care” and carries evidence of first-quarter 2026 results, an announcement of those results for May 7, 2026, and fourth-quarter and full-year 2025 results. The product rail here is therefore consumer care, but the supplied evidence does not name specific current product launches or sales figures by brand. The useful point is narrower and stronger: this is an operating consumer-health company whose official source trail connects earnings, filings, product-category disclosure, supply-chain reporting and legal notes.

The latest parsed SEC financials show a balance sheet with $26.85B of assets, $16.25B of liabilities and $10.61B of stockholders’ equity attributable to parent at the 10-Q period ending 2026-03-29. Cash and cash equivalents were $1.07B, inventory was $1.67B, net cash provided by operating activities was $489.0M, payments to acquire property, plant and equipment were $139.0M, and research and development expense was $84.0M. The company also reported a $19.0M increase in inventories for the same period.

The supplied rail does not include a TradingView route, price level, moving average, volume figure or chart snapshot, so the chart context cannot be made up. The market mechanism that can be described is the public-company evidence mechanism: SEC filings, official issuer releases, insider and resale disclosure forms, product-category filing language, cash flow figures, inventory movement and legal risk notes.

What changed most recently in the public file was disclosure activity. SEC EDGAR lists a Form 4 dated 2026-06-12, a Form 144 dated 2026-06-10, an SD conflict minerals filing dated 2026-05-28, several Form 4 filings dated 2026-05-26, an 8-K dated 2026-05-22, the 10-Q dated 2026-05-07, and an 8-K dated 2026-05-07 announcing first-quarter results for the fiscal quarter ended 2026-03-29.

The legal and product notes are not decorative. The 10-Q evidence says J&J acquired Pfizer’s OTC business in 2006, including U.S. OTC Zantac rights, then on-sold those rights to Boehringer Ingelheim as a condition to merger control approval, with BI assuming product liability risk for U.S. sales from and after December 2006. It also says putative class actions began in September 2023 after an NDAC vote against the company and affiliates, with other sellers and manufacturers of PE-containing products also named.